European Union - English - EMA (European Medicines Agency)

janssen-cilag international n.v.   - paliperidone palmitate - schizophrenia - psycholeptics - byannli (previously paliperidone janssen-cilag international) a 6 monthly injection, is indicated for the maintenance treatment of schizophrenia in adult patients who are clinically stable on 1 monthly or 3 monthly paliperidone palmitate injectable products (see section 5.1).

United Kingdom - English - myHealthbox

janssen-cilag ltd - risperidone - tablets - 4 mg - other antipsychotic - it is indicated for the treatment of schizophrenia; for the treatment of moderate to severe manic episodes associated with bipolar disorders; in patients with moderate to severe alzheimer's dementia; forf persistent aggression in conduct disorder in children from the age of 5 years and adolescents with subaverage intellectual functioning or mental retardation

United Kingdom - English - myHealthbox

janssen-cilag ltd - risperidone - tablets - 3 mg - other antipsychotic - it al is used to treat the following: schizophrenia, mania, aggression in people with alzheimer’s dementia, aggression in intellectually disabled children (at least 5 years of age) and adolescents with conduct disorder.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

janssen-cilag ltd - risperidone - orodispersible tablet - 4mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

janssen-cilag ltd - risperidone - orodispersible tablet - 3mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

janssen-cilag ltd - miconazole nitrate - cutaneous cream - 20mg/1gram

Australia - English - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - ad26.cov2.s, quantity: 50000000000 vp - injection, suspension - excipient ingredients: sodium chloride; polysorbate 80; sodium hydroxide; hydroxypropylbetadex; citric acid monohydrate; sodium citrate dihydrate; ethanol absolute; hydrochloric acid; water for injections - covid-19 vaccine janssen has provisional approval for the indication:,covid-19 vaccine janssen is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 18 years of age and older.,the use of this vaccine should be in accordance with official recommendations. the decision has been made on the basis of short term efficacy and safety data. continued approval is dependent upon the evidence of longer-term efficacy and safety from ongoing clinical trials and post-market assessment.

United Kingdom - English - myHealthbox

janssen-cilag ltd - methylphenidate hydrochloride - prolonged-release tablet - 36 mg - centrally acting sympathomimetics - it is indicated as part of a comprehensive treatment programme for attention deficit hyperactivity disorder (adhd) in children aged 6 years of age and over when remedial measures alone prove insufficient

United Kingdom - English - myHealthbox

janssen-cilag ltd - methylphenidate hydrochloride - prolonged-release tablet - 18 mg - centrally acting sympathomimetics - it is indicated as part of a comprehensive treatment programme for attention deficit hyperactivity disorder (adhd) in children aged 6 years of age and over when remedial measures alone prove insufficient.

United Kingdom - English - myHealthbox

janssen-cilag ltd - methylphenidate hydrochloride - prolonged-release tablet - 54 mg - centrally acting sympathomimetics - it is indicated as part of a comprehensive treatment programme for attention deficit hyperactivity disorder in children aged 6 years of age and over when remedial measures alone prove insufficient.